Tagged with Trials,

Turkey After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu,…

Denmark Per Jørgensen, deputy director of Copenhagen University Hospital (Rigshospitalet), discusses pandemic management, clinical trial collaborations with private industry, translational research, and the demands that the hospitals of the future will need to adapt to.   Big and specialized hospitals in Denmark such as ours are in a unique position to…

Europe The Lymphoma Coalition’s Natacha Bolaños outlines the fundamentals of the lymphoma patient experience today, the growing number of innovative new treatment options available, and the issues surrounding their integration as earlier lines of treatment.   CAR-T is not necessarily the best treatment option for everyone. There could be other second-best…

Turkey The president of the Turkish Health Institutes (TUSEB), Dr Erhan Akdoğan, provides a behind-the-scenes look at the development process of Turkovac, the country’s first homegrown COVID-19 vaccine which is currently undergoing phase III clinical studies. Dr Akdoğan took over TUSEB, and the nine institutes under its responsibility, in the middle…

Denmark Industry veteran Patrik Forsell oversees Takeda’s operations in Denmark. Here, Forsell talks through how sizeable shifts in the company’s global portfolio and focus over the past four years have played out at the Danish level, the increasingly challenging market access situation for rare disease treatments in the country, and how…

Denmark. AbbVie In a wide-ranging interview, AbbVie’s Linn Mandahl discusses how the reorganisation of Scandinavian operations back in 2018 has put the company back on a growth trajectory in the region. Mandahl also touches on the challenges and opportunities in terms of portfolio and culture that the Allergan acquisition has brought about;…

Denmark MSD’s Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market, drawing on experiences in her native UK to compare the two countries’ market access environments for innovative products. Williams also touches on MSD’s sizeable clinical trial footprint in Denmark, the…

Saudi Arabia Dr Ahmed Alaskar is executive director of the King Abdullah International Medical Research Center (KAIMRC); president of the Saudi Society of Blood and Marrow Transplantation (SSBMT); professor of Consultant Adult Hematology & HSCT at King Saud bin Abdulaziz University for Health Sciences; and chairman of the Riyadh Global Medical Biotechnology…

Denmark Spanish native Enrique Álvarez gives an overview of Denmark’s importance to Merck as a key European early launch market, a crucial clinical trial destination, and home to a treasure trove of holistic patient data. Álvarez also outlines the increasing challenges around market access in the country and his talent development…

Denmark Healthcare DENMARK is a non-profit organization and public-private partnership representing Danish healthcare stakeholders internationally. Jakob Skaarup Nielsen, its CEO, highlights the Nordic country’s “treasure trove” of health data, the efforts to digitalize even further and the population’s open mind when it comes to participating in clinical trials. Moreover, he outlines…

Saudi Arabia Clinical trials provide a pathway to innovation for clinicians and patients in countries like Saudi Arabia and form a key element of the country’s Vision 2030 national plan. As Saudi transitions away from oil towards becoming a knowledge-based economy, it is hoping to attract ever more international pharma companies to…

Turkey Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for a revision of the good clinical practice guidelines. Moreover, he explains why TITCK becoming an International Council for Harmonisation (ICH)…